{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:09:24Z","timestamp":1761512964154},"reference-count":84,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.semarthrit.2011.01.005","type":"journal-article","created":{"date-parts":[[2011,4,21]],"date-time":"2011-04-21T20:34:58Z","timestamp":1303418098000},"page":"157-169","source":"Crossref","is-referenced-by-count":25,"title":["Clinical Utility of Serum Bone Turnover Markers in Postmenopausal Osteoporosis Therapy Monitoring: A Systematic Review"],"prefix":"10.1016","volume":"41","author":[{"given":"Thomas","family":"Funck-Brentano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Biver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Chopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Bouvard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Souberbielle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Garnero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.semarthrit.2011.01.005_bib1","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.semarthrit.2011.01.005_bib2","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum CrossLaps One Step ELISA","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","article-title":"Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis","volume":"47","author":"Garnero","year":"2001","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.semarthrit.2011.01.005_bib4","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semarthrit.2011.01.005_bib5","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA","author":"Glover","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib6","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2008","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.semarthrit.2011.01.005_bib7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1359\/jbmr.2003.18.10.1789","article-title":"Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.01.005_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.01.005_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","article-title":"Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy","volume":"26","author":"Christgau","year":"2000","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.01.005_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1373\/clinchem.2007.094953","article-title":"Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis","volume":"54","author":"Garnero","year":"2008","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1053\/ajkd.2002.35692","article-title":"Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients","volume":"40","author":"Ueda","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2011.01.005_bib12","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","article-title":"Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability","volume":"13","author":"Hannon","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.01.005_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","author":"Eastell","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","article-title":"Endocrine regulation of energy metabolism by the skeleton","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1681\/ASN.V73506","article-title":"Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients","volume":"7","author":"Urena","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.01.005_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1479-8077.2006.00161.x","article-title":"Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia","volume":"9","author":"Lau","year":"2006","journal-title":"APLAR J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.01.005_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1742-1241.2008.01911.x","article-title":"Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club","volume":"63","author":"Bergmann","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib19","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2011.01.005_bib20","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial","volume":"21","author":"Bauer","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","author":"Seibel","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover","volume":"39","author":"Delmas","year":"2006","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00198-009-0940-z","article-title":"Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover","volume":"21","author":"Collette","year":"2010","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.semarthrit.2011.01.005_bib27","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1210\/jc.84.7.2363","article-title":"Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study","volume":"84","author":"Ravn","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1507\/endocrj.52.667","article-title":"Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis","volume":"52","author":"Kim","year":"2005","journal-title":"Endocr J"},{"issue":"10","key":"10.1016\/j.semarthrit.2011.01.005_bib29","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s001980170117","article-title":"Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate","volume":"12","author":"Watts","year":"2001","journal-title":"Osteoporos Int"},{"issue":"Pt 6","key":"10.1016\/j.semarthrit.2011.01.005_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/000456329803500603","article-title":"Clinical usefulness of bone alkaline phosphatase in osteoporosis","volume":"35","author":"Kyd","year":"1998","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib32","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jc.2005-1712","article-title":"Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis","volume":"91","author":"Bauer","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bone.2003.10.004","article-title":"Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk","volume":"34","author":"Reginster","year":"2004","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.semarthrit.2011.01.005_bib35","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.semarthrit.2011.01.005_bib37","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semarthrit.2011.01.005_bib38","article-title":"Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years","author":"Bruy\u00e8re","year":"2009","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib39","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semarthrit.2011.01.005_bib40","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2008-1122","article-title":"Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates","author":"Burnett-Bowie","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jocd.2010.01.007","article-title":"The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy","volume":"13","author":"Hochberg","year":"2010","journal-title":"J Clin Densitom"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/00365510701832237","article-title":"Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy","volume":"68","author":"Kumm","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"issue":"9","key":"10.1016\/j.semarthrit.2011.01.005_bib43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-004-1819-7","article-title":"Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide","volume":"16","author":"Tahtela","year":"2005","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib44","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"9","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib45","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1756-185X.2009.01413.x","article-title":"Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women","volume":"12","author":"Kung","year":"2009","journal-title":"Int J Rheum Dis"},{"issue":"24","key":"10.1016\/j.semarthrit.2011.01.005_bib47","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.semarthrit.2011.01.005_bib49","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2011.01.005_bib50","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib51","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"issue":"9","key":"10.1016\/j.semarthrit.2011.01.005_bib52","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","article-title":"Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates","volume":"68","author":"Lazarovici","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"issue":"12","key":"10.1016\/j.semarthrit.2011.01.005_bib53","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","article-title":"Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Kwon","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"10.1016\/j.semarthrit.2011.01.005_bib54","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","article-title":"Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1359\/jbmr.090203","article-title":"Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw","volume":"24","author":"Baim","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib56","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.joms.2008.01.054","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"66","author":"Khosla","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"10.1016\/j.semarthrit.2011.01.005_bib57","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib58","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/17453670710015580","article-title":"Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy\u2014a case report","volume":"79","author":"Sayed-Noor","year":"2008","journal-title":"Acta Orthop"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?","volume":"39","author":"Kwek","year":"2008","journal-title":"Injury"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib60","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMc080861","article-title":"More on atypical fractures of the femoral diaphysis","volume":"359","author":"Kwek","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2011.01.005_bib61","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","article-title":"Severely suppressed bone turnover and atypical skeletal fragility","volume":"93","author":"Visekruna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.01.005_bib62","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"Neviaser","year":"2008","journal-title":"J Orthop Trauma"},{"issue":"12","key":"10.1016\/j.semarthrit.2011.01.005_bib63","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2011.01.005_bib64","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study","volume":"20","author":"Lenart","year":"2009","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib65","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.semarthrit.2011.01.005_bib66","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","article-title":"Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis","volume":"355","author":"Armamento-Villareal","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case\/case series studies","volume":"47","author":"Giusti","year":"2010","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.01.005_bib68","first-page":"571","article-title":"[Prescription of bone remodeling markers in hospitals]","volume":"60","author":"Souberbielle","year":"2002","journal-title":"Ann Biol Clin (Paris)"},{"issue":"8","key":"10.1016\/j.semarthrit.2011.01.005_bib69","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.01.005_bib70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1297-319X(03)00046-0","article-title":"Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency","volume":"70","author":"Grados","year":"2003","journal-title":"Joint Bone Spine"},{"issue":"11","key":"10.1016\/j.semarthrit.2011.01.005_bib71","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1210\/jc.2002-021968","article-title":"Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation","volume":"88","author":"Grados","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.semarthrit.2011.01.005_bib72","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1517\/14656560903140533","article-title":"Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence","volume":"10","author":"Rabenda","year":"2009","journal-title":"Exp Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-008-0698-8","article-title":"Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience","volume":"20","author":"Briot","year":"2009","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.01.005_bib74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbspin.2006.05.011","article-title":"How long should patients take medications for postmenopausal osteoporosis?","volume":"74","author":"Briot","year":"2007","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib75","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001980070097","article-title":"Study subjects and ordinary patients","volume":"11","author":"Dowd","year":"2000","journal-title":"Osteoporos Int"},{"issue":"15","key":"10.1016\/j.semarthrit.2011.01.005_bib76","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.108.824151","article-title":"Statin adherence and risk of accidents: a cautionary tale","volume":"119","author":"Dormuth","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.01.005_bib77","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00774-007-0807-3","article-title":"Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis","volume":"26","author":"Majima","year":"2008","journal-title":"J Bone Miner Metab"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib78","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S8756-3282(99)00087-3","article-title":"A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover","volume":"24","author":"Garnero","year":"1999","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.01.005_bib79","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1359\/jbmr.1999.14.4.602","article-title":"Monitoring alendronate therapy for osteoporosis","volume":"14","author":"Braga de Castro Machado","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.semarthrit.2011.01.005_bib80","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.01.005_bib81","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.semarthrit.2011.01.005_bib82","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1373\/clinchem.2005.055541","article-title":"Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy","volume":"51","author":"Ivaska","year":"2005","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.01.005_bib83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(03)00168-6","article-title":"Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis","volume":"33","author":"Ravn","year":"2003","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.01.005_bib84","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/BF02850205","article-title":"Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis","volume":"23","author":"Atmaca","year":"2006","journal-title":"Adv Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017211000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017211000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:32:55Z","timestamp":1637541175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017211000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0049017211000254"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2011.01.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}